The 'Long R3' modification
As a result, insurers are much more likely to cover GLP-1 agonists for diabetes than for weight loss
And while protein is important, its not the only piece of the puzzle
Overview of the FDAs Compounded Semaglutide Manufacturing Ban In response to concerns about safety, efficacy, and regulatory oversight, the FDA issued a ruling requiring compounding pharmacies to stop manufacturing compounded semaglutide by May 22, 2025
Main limit: many mechanism claims rest on preclinical (lab/animal) work
There really needs to be a conversation across all of the different departments packaging, branding, messaging, obviously formulation. Bray added that customer conversations confirm the shift: Everywhere you look, all the customers that were talking to, theyre telling us how its really impacting the decisions theyre going to make and how theyre going to go to market. Signals From Big Brands Austin pointed to large manufacturers already moving in response
